3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Sorafenib
3
vandetanib
2
alectinib
2
Sodium
2
Magnetic Resonance Spectroscopy
2
Imatinib Mesylate
2
Bevacizumab
2
tremelimumab
1
temsirolimus
1
ponatinib
1
perflutren
1
pembrolizumab
1
methyl N-acetylsibirosaminide
1
lenvatinib
1
gallium 68 PSMA-11
1
fosbretabulin
1
durvalumab
1
combretastatin
1
cobimetinib
1
cabozantinib
1
X-Rays
1
Valproic Acid
1
Thyroxine
1
Technetium Tc 99m Sestamibi
1
Sirolimus
1
Radiofrequency Ablation
1
Presenilin-1
1
Paclitaxel
1
PLX8394
1
Lubricant Eye Drops
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Thyroid Neoplasms
×
combretastatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts